Recent advances in the study of asthma have led to the development of novel treatment approaches for severe and uncontrolled asthma. Additionally, data on Short Acting Beta Agonist (SABA) use has implications on asthma control and outcomes. Updated guidelines reflect these emerging data and highlight the need for improved asthma control in many patients.
This brief, case-based Decision Point activity presents learners with common clinical challenges in the management of patients with poorly controlled asthma. A recognized expert in asthma then discusses these issues in the context of emerging evidence and guidelines.
Upon completion of this activity, learners should be able to:
- Recognize the association between Short Acting Beta Agonist (SABA) inhaler use, asthma control, and outcomes
- Escalate asthma therapies in patients with suboptimally-controlled moderate-to-severe disease, utilizing guidelines to inform recommendations
Start Date: 02/22/2022
Expiration Date: 02/21/2023
Target Audience: Nurse Practitioners, Physician Assistants, Physicians, and other clinicians who treat patients with asthma
Format: Decision Points
Estimated Time To Complete CME Activity: 15 minutes
0.25 AMA PRA Category 1 CreditsTM
0.25 AANP Contact hours which includes 0.25 pharmacology hours
Hardware/Software Requirements: Any web browser
Course Runs: Feb 22nd 2022 – Feb 21st 2023
Register now to gain access to this course. Register Now